CA2112678A1 - Indoles - Google Patents

Indoles

Info

Publication number
CA2112678A1
CA2112678A1 CA002112678A CA2112678A CA2112678A1 CA 2112678 A1 CA2112678 A1 CA 2112678A1 CA 002112678 A CA002112678 A CA 002112678A CA 2112678 A CA2112678 A CA 2112678A CA 2112678 A1 CA2112678 A1 CA 2112678A1
Authority
CA
Canada
Prior art keywords
formula
alkyl
compound
aryl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002112678A
Other languages
English (en)
French (fr)
Inventor
Julian Blagg
Kelvin Cooper
Peter L. Spargo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2112678A1 publication Critical patent/CA2112678A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CA002112678A 1991-07-24 1992-07-20 Indoles Abandoned CA2112678A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9115951.7 1991-07-24
GB919115951A GB9115951D0 (en) 1991-07-24 1991-07-24 Indoles

Publications (1)

Publication Number Publication Date
CA2112678A1 true CA2112678A1 (en) 1993-02-04

Family

ID=10698873

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002112678A Abandoned CA2112678A1 (en) 1991-07-24 1992-07-20 Indoles
CA002112689A Abandoned CA2112689A1 (en) 1991-07-24 1992-07-20 Indoles

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002112689A Abandoned CA2112689A1 (en) 1991-07-24 1992-07-20 Indoles

Country Status (20)

Country Link
EP (2) EP0598750A1 (pt)
JP (2) JPH06509336A (pt)
CN (2) CN1068816A (pt)
AU (2) AU2327192A (pt)
BR (1) BR9206306A (pt)
CA (2) CA2112678A1 (pt)
CZ (1) CZ13694A3 (pt)
FI (2) FI940311A0 (pt)
GB (1) GB9115951D0 (pt)
HU (1) HU9400199D0 (pt)
IE (2) IE922387A1 (pt)
IL (2) IL102544A0 (pt)
MX (1) MX9204342A (pt)
NO (1) NO940237L (pt)
NZ (1) NZ243687A (pt)
PT (2) PT100717A (pt)
SK (1) SK8494A3 (pt)
TW (1) TW223060B (pt)
WO (2) WO1993002051A1 (pt)
ZA (2) ZA925546B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9204024D0 (en) * 1992-02-25 1992-04-08 Fujisawa Pharmaceutical Co Indole derivatives
GB9302577D0 (en) * 1993-02-10 1993-03-24 Fujisawa Pharmaceutical Co Indole derivatives
US5530019A (en) * 1993-04-05 1996-06-25 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives useful as testosterone 5α-reductase inhibitors
GB9310092D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co Indole derivatives
GB9317096D0 (en) * 1993-08-17 1993-09-29 Pfizer Ltd Indoles
CA2186499A1 (en) * 1994-03-30 1995-10-12 Kiyoshi Yoshida Indole derivative and medicine containing the same
GB9409583D0 (en) * 1994-05-13 1994-07-06 Pfizer Ltd Indoles
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
ES2283933T3 (es) 1997-05-14 2007-11-01 Atherogenics, Inc. Ester del acido succinico de probucol para la inhibicion de la expresion de vcam-1.
US6670398B2 (en) 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US7417063B2 (en) 2004-04-13 2008-08-26 Bristol-Myers Squibb Company Bicyclic heterocycles useful as serine protease inhibitors
FR2893615B1 (fr) * 2005-11-18 2008-03-07 Sanofi Aventis Sa Derives de 3-acylindole, leur preparation et leur application en therapeutique
PE20090159A1 (es) 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
CN101686676A (zh) 2007-03-26 2010-03-31 沙路特里亚制药有限责任公司 用于治疗糖尿病的方法和普罗布考衍生物的组合物
US10703969B2 (en) * 2016-09-27 2020-07-07 Kaohsiung Medical University Detection method for quaternary ammonium compound having γ-carboxyl group

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9011335D0 (en) * 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
WO1993005020A1 (en) * 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase

Also Published As

Publication number Publication date
NO940237D0 (no) 1994-01-24
CZ13694A3 (en) 1994-07-13
AU2327092A (en) 1993-02-23
NO940237L (no) 1994-01-24
MX9204342A (es) 1994-03-31
IE922387A1 (en) 1993-01-27
FI940311A (fi) 1994-01-21
NZ243687A (en) 1994-12-22
CA2112689A1 (en) 1993-02-04
CN1068816A (zh) 1993-02-10
IE922386A1 (en) 1993-01-27
WO1993002050A1 (en) 1993-02-04
EP0598754A1 (en) 1994-06-01
FI940311A0 (fi) 1994-01-21
SK8494A3 (en) 1994-11-09
ZA925546B (en) 1994-01-24
CN1068817A (zh) 1993-02-10
FI940310A (fi) 1994-01-21
PT100717A (pt) 1993-08-31
ZA925547B (en) 1994-01-24
JPH06511483A (ja) 1994-12-22
AU655662B2 (en) 1995-01-05
AU2327192A (en) 1993-02-23
HU9400199D0 (en) 1994-05-30
FI940310A0 (fi) 1994-01-21
WO1993002051A1 (en) 1993-02-04
GB9115951D0 (en) 1991-09-11
IL102545A0 (en) 1993-01-14
BR9206306A (pt) 1994-11-08
JPH06509336A (ja) 1994-10-20
TW223060B (pt) 1994-05-01
IL102544A0 (en) 1993-01-14
EP0598750A1 (en) 1994-06-01
PT100718A (pt) 1993-08-31

Similar Documents

Publication Publication Date Title
JP5036648B2 (ja) Mglur5アンタゴニスト活性を有するアセチレン誘導体
US6136843A (en) Indole derivatives useful as endothelin receptor antagonists
CA2112678A1 (en) Indoles
JPH0710838A (ja) sPLA2阻害剤1H−インドール−3−酢酸ヒドラジド
EP0628040B1 (en) Indole derivatives as steroid 5 alpha-reductase inhibitors
JP2833865B2 (ja) 5−アルファ−リダクターゼ−1−阻害剤としてのインドール誘導体
US5840758A (en) Oxime derivatives of fenamates as inhibitors of prostaglandin biosynthesis
US5922747A (en) Indole derivatives as steroid 5α-reductase inhibitors
JPH0560462B2 (pt)
WO1995031453A1 (en) Indole derivatives as 5 alpha-reductase 1 inhibitors
WO1995023143A1 (en) Indole derivatives as testosterone-5-alpha-reductase inhibitors
JPH0912566A (ja) オキサインデン誘導体及びその製法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued